Compounds > dobutamine
Page last updated: 2024-08-23

dobutamine and desipramine

dobutamine has been researched along with desipramine in 11 studies

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19902 (18.18)18.7374
1990's1 (9.09)18.2507
2000's2 (18.18)29.6817
2010's6 (54.55)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Topliss, JG; Yoshida, F1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Jones, LH; Nadanaciva, S; Rana, P; Will, Y1
Chen, EC; Chien, HC; Giacomini, KM; Huang, Y; Khuri, N; Liang, X; Sali, A; Stecula, A; Yee, SW1
O'Donnell, JM1
Handley, SL; Singh, L1
Ankermann, H; Ankermann, I1
Himura, Y; Kashiki, M; Liang, CS; Stevens, SY1
Pattij, T; Schetters, D; Schoffelmeer, AN; van Gaalen, MM1

Reviews

1 review(s) available for dobutamine and desipramine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

10 other study(ies) available for dobutamine and desipramine

ArticleYear
QSAR model for drug human oral bioavailability.
    Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13

    Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship

2000
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
    Bioorganic & medicinal chemistry letters, 2016, 08-15, Volume: 26, Issue:16

    Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone

2016
Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1; SLC22A1).
    Journal of medicinal chemistry, 2017, 04-13, Volume: 60, Issue:7

    Topics: Drug Discovery; HEK293 Cells; Humans; Ligands; Molecular Docking Simulation; Organic Cation Transporter 1; Small Molecule Libraries

2017
Behavioral effects of beta adrenergic agonists and antidepressant drugs after down-regulation of beta-2 adrenergic receptors by clenbuterol.
    The Journal of pharmacology and experimental therapeutics, 1990, Volume: 254, Issue:1

    Topics: Adrenergic beta-Agonists; Animals; Antidepressive Agents; Benzimidazoles; Clenbuterol; Conditioning, Operant; Desipramine; Dobutamine; Down-Regulation; Ethanolamines; Male; Prenalterol; Propanolamines; Rats; Rats, Inbred Strains; Receptors, Adrenergic, beta

1990
Chronic antidepressant treatment reduces central beta-adrenoceptor sensitivity in a behavioural test.
    European journal of pharmacology, 1986, Aug-07, Volume: 127, Issue:1-2

    Topics: 5-Hydroxytryptophan; Albuterol; Animals; Antidepressive Agents; Behavior, Animal; Desipramine; Dobutamine; Drug Resistance; Drug Synergism; Iprindole; Male; Mice; Prenalterol; Receptors, Adrenergic, beta

1986
[Calorigenic action of dopamine and dobutamine].
    Biomedica biochimica acta, 1983, Volume: 42, Issue:10

    Topics: Animals; Calorimetry; Catecholamines; Desipramine; Dobutamine; Dopamine; Energy Metabolism; Female; Kinetics; Norepinephrine; Oxygen Consumption; Rats; Rats, Inbred Strains

1983
Differential pre- and postsynaptic effects of desipramine on cardiac sympathetic nerve terminals in RHF.
    American journal of physiology. Heart and circulatory physiology, 2002, Volume: 283, Issue:5

    Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Animals; Blood Pressure; Cardiotonic Agents; Desipramine; Dobutamine; Dogs; Heart Failure; Immunohistochemistry; Myocardial Contraction; Myocardium; Neuropeptide Y; Norepinephrine; Organ Size; Presynaptic Terminals; Receptors, Adrenergic, beta; Sympathetic Nervous System; Tyrosine 3-Monooxygenase; Ventricular Dysfunction, Right

2002
On the improvement of inhibitory response control and visuospatial attention by indirect and direct adrenoceptor agonists.
    Psychopharmacology, 2012, Volume: 219, Issue:2

    Topics: Adrenergic Agonists; Animals; Attention; Choice Behavior; Clenbuterol; Clonidine; Desipramine; Dobutamine; Dose-Response Relationship, Drug; Inhibition, Psychological; Isoproterenol; Male; Methylphenidate; Phenylephrine; Rats; Rats, Wistar; Reaction Time; Serial Learning

2012